Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Inclusion Criteria: * Chinese healthy men or women aged 18 to 55 years old at screening (inclusive）; * Serum LDL-C concentration between 1.8 mmol/L and 4.9 mmol/L (inclusive）at screening; * Body mass index between 19 and 28 kg/m2 (inclusive); * Willing to maintain the current regular diet and physical activity; * Female subjects and male subject's partner who could become pregnant should take effective contraceptions during the treatment period and 6 months after dosing; * Without any medical history of serious diseases; * Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent. Exclusion Criteria: * Breast-feeding or pregnant women; * History of allergic reaction; * Previously received any anti-PCSK-9 treatment; * Vital signs, physical examination, clinical laboratory test, 12-lead ECG, and chest X-ray are abnormal with clinical significance; * Not willing to stop intense physical activities (such as weight lifting or long-distance running) before 72 hours of the scheduled visits; * Any hospitalization within one month before screening, or major surgery within six months before screening, or any other unstable medical condition; * Received an investigational chemical agent within 30 days before dosing； * Received an investigational biological agent within 90 days before dosing； * Use of medications including over-the-counter medication within 14 days or less than 5 half-lifes of the agent; * Use of herb,vitamins or nutraceutical in order to alter serum lipids; * Positive screen of hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection at screening； * History or clinical evidence of alcohol or drugs of abuse within 12 months before screening; * With any consumption of alcohol and caffeinated beverages within 72 hours prior to and during the trial; * Blood donations or blood loss 200 ml and more within 2 months before screening; * History of organ transplantation or malignant tumor; * Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment.